Article: GSK returns rights to Futura Medical's ED gel.(GlaxoSmithKline)(Brief article)

Drug major GlaxoSmithKline has returned the development rights to MED2002, a topical gel for erectile dysfunction, to its originator, fellow UK-based Futura Medical, sending shares in the latter down 30% to 41 pence on the day of the news, May 15.

According to Futura, current priorities within GSK meant that they were unlikely in the near future to approve a marketing agreement for the agent, which recently completed Phase II trials. The companies' negotiation over global distribution rights for the provision of pain relief using Futura's transdermal delivery technology is unaffected by this decision on MED2002.

During the period of exclusivity with GSK, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!